An American biotechnology company has announced that a bacteriophage designed using an artificial intelligence model has been used for the treatment of a human for the first time, marking a significant step toward introducing AI-created biological solutions into clinical practice.
This treatment was administered through an exceptional compassionate use or right-to-try mechanism, which is intended for critically ill patients who cannot be treated by other means and are suffering from antibiotic-resistant bacterial infections. Scientists note that the multimodal genomic model used can process DNA, RNA, and protein data, as well as predict their interactions with bacteria.
Prior to administering it to the patient, specialists took the antibiotic-resistant strain from the patient and tested a mixture of AI-created bacteriophages under laboratory conditions. Laboratory testing successfully eliminated the target bacteria entirely, after which clinical application was permitted.
Bacteriophages are specialized viruses that attack only bacteria and are considered a powerful alternative to antibiotics. Despite this success, the company has not yet released details regarding the patient's condition, citing the need for privacy, and reminded that a single case is not yet sufficient to fully establish efficacy.
Applying artificial intelligence to the design of biological samples opens new horizons in medicine, particularly when conventional drugs are no longer effective. These technologies enable a personalized approach in cases of extremely complex infections.
Nonetheless, such innovations still have a long path of extensive clinical trials ahead of them before achieving widespread adoption.
